Research Progress of Methylation in Endometrial Carcinoma

doi:10.12280/gjfckx.20220266

Abstract

Abstract:

Methylation is one of the important elements of epigenetics, and abnormal methylation is closely related to malignant tumor cell proliferation, autophagy, apoptosis, intercellular adhesion, infiltration and metastasis. Endometrial cancer is a common malignancy of the female reproductive system. Studies have shown that abnormal methylation of genes is associated with risk factors, types, tumor progression, early diagnosis, chemoresistance, progesterone resistance and prognostic assessment of endometrial carcinoma. Specific methylation markers can be used for early diagnosis and prognostic assessment of endometrial carcinoma. Regulating the methylation status of key genes can improve the sensitivity of endometrial carcinoma cells to chemotherapy and progesterone. This article provides an overview of research advances in DNA, RNA and histone methylation in the pathogenesis, early diagnosis, drug therapy and prognostic assessment of endometrial carcinoma.

Key words: Endometrial neoplasms, Methylation, Epigenesis, genetic, Diagnosis, Therapy, Prognosis

WANG Xiang-lian, XU Wei, ZHU Shu, WANG Xiu-li. Research Progress of Methylation in Endometrial Carcinoma[J]. Journal of International Obstetrics and Gynecology, 2023, 50(1): 6-10.

References 35

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Sobel M, Simpson AN, Ferguson SE. Endometrial cancer[J]. CMAJ, 2021, 193(36):E1423. doi: 10.1503/cmaj.202731. doi: 10.1503/cmaj.202731
[3]	Nagashima M, Miwa N, Hirasawa H, et al. Genome-wide DNA methylation analysis in obese women predicts an epigenetic signature for future endometrial cancer[J]. Sci Rep, 2019, 9(1):6469. doi: 10.1038/s41598-019-42840-4. doi: 10.1038/s41598-019-42840-4 pmid: 31015518
[4]	Polusani SR, Huang YW, Huang G, et al. Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer[J]. Cancer Res, 2019, 79(1):196-208. doi: 10.1158/0008-5472.CAN-18-1615. doi: 10.1158/0008-5472.CAN-18-1615
[5]	Mimouni N, Paiva I, Barbotin AL, et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process[J]. Cell Metab, 2021, 33(3):513-530.e8. doi: 10.1016/j.cmet.2021.01.004. doi: 10.1016/j.cmet.2021.01.004 pmid: 33539777
[6]	Tamm-Rosenstein K, Simm J, Suhorutshenko M, et al. Changes in the transcriptome of the human endometrial Ishikawa cancer cell line induced by estrogen, progesterone, tamoxifen, and mifepristone (RU486) as detected by RNA-sequencing[J]. PLoS One, 2013, 8(7):e68907. doi: 10.1371/journal.pone.0068907. doi: 10.1371/journal.pone.0068907
[7]	Kim J, Kong JK, Yang W, et al. DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer[J]. Cancers (Basel), 2018, 10(9):279. doi: 10.3390/cancers10090279. doi: 10.3390/cancers10090279
[8]	Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer, 2022, 150(1):7-17. doi: 10.1002/ijc.33763. doi: 10.1002/ijc.33763
[9]	Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions[J]. Gynecol Oncol, 2015, 136(1):3-7. doi: 10.1016/j.ygyno.2014.09.009. doi: 10.1016/j.ygyno.2014.09.009 pmid: 25238946
[10]	Ren C, Liu Y, Wang Y, et al. Identification of novel Lynch syndrome mutations in Chinese patients with endometriod endometrial cancer[J]. Cancer Biol Med, 2020, 17(2):458-467. doi: 10.20892/j.issn.2095-3941.2019.0295. doi: 10.20892/j.issn.2095-3941.2019.0295 pmid: 32587781
[11]	Seeber LM, Zweemer RP, Marchionni L, et al. Methylation profiles of endometrioid and serous endometrial cancers[J]. Endocr Relat Cancer, 2010, 17(3):663-673. doi: 10.1677/ERC-10-0014. doi: 10.1677/ERC-10-0014
[12]	Zhang B, Xing X, Li J, et al. Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers[J]. BMC Genomics, 2014, 15(1):868. doi: 10.1186/1471-2164-15-868. doi: 10.1186/1471-2164-15-868
[13]	Bartosch C, Lopes JM, Jerónimo C. Epigenetics in endometrial carcinogenesis-part 1: DNA methylation[J]. Epigenomics, 2017, 9(5):737-755. doi: 10.2217/epi-2016-0166. doi: 10.2217/epi-2016-0166 pmid: 28470096
[14]	Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013, 497(7447):67-73. doi: 10.1038/nature12113. doi: 10.1038/nature12113
[15]	Huang W, Kong F, Li R, et al. Emerging Roles of m(6)A RNA Methylation Regulators in Gynecological Cancer[J]. Front Oncol, 2022, 12:827956. doi: 10.3389/fonc.2022.827956. doi: 10.3389/fonc.2022.827956
[16]	Favier A, Rocher G, Larsen AK, et al. MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review[J]. Cancers (Basel), 2021, 13(5):1137. doi: 10.3390/cancers13051137. doi: 10.3390/cancers13051137
[17]	Li B, Lu W, Qu J, et al. DICER1 regulates endometrial carcinoma invasion via histone acetylation and methylation[J]. J Cancer, 2017, 8(6):933-939. doi: 10.7150/jca.17435. doi: 10.7150/jca.17435 pmid: 28529604
[18]	Xiao Z, He Y, Liu C, et al. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation[J]. Oncol Rep, 2019, 41(5):2667-2678. doi: 10.3892/or.2019.7067. doi: 10.3892/or.2019.7067 pmid: 30896884
[19]	Sangtani A, Wang C, Weaver A, et al. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection[J]. Gynecol Oncol, 2020, 156(2):387-392. doi: 10.1016/j.ygyno.2019.11.028. doi: S0090-8258(19)31679-8 pmid: 31787246
[20]	Multinu F, Chen J, Madison JD, et al. Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer[J]. Gynecol Oncol, 2020, 156(3):682-688. doi: 10.1016/j.ygyno.2019.12.023. doi: S0090-8258(19)31844-X pmid: 31902687
[21]	Inoue F, Sone K, Toyohara Y, et al. Targeting Epigenetic Regulators for Endometrial Cancer Therapy: Its Molecular Biology and Potential Clinical Applications[J]. Int J Mol Sci, 2021, 22(5):2305. doi: 10.3390/ijms22052305. doi: 10.3390/ijms22052305
[22]	van den Helder R, Wever B, van Trommel NE, et al. Non-invasive detection of endometrial cancer by DNA methylation analysis in urine[J]. Clin Epigenetics, 2020, 12(1):165. doi: 10.1186/s13148-020-00958-7. doi: 10.1186/s13148-020-00958-7 pmid: 33143739
[23]	den Helder RV, Wever BM, van Trommel JA, et al. DNA methylation markers for endometrial cancer detection in minimally invasive samples: a systematic review[J]. Epigenomics, 2020, 12(18):1661-1672. doi: 10.2217/epi-2020-0164. doi: 10.2217/epi-2020-0164 pmid: 32938224
[24]	Zhou JW, Tang JJ, Sun W, et al. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma[J]. Mol Med, 2019, 25(1):11. doi: 10.1186/s10020-019-0079-0. doi: 10.1186/s10020-019-0079-0
[25]	Yanokura M, Banno K, Aoki D. MicroRNA-34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel[J]. Int J Oncol, 2020, 57(5):1145-1156. doi: 10.3892/ijo.2020.5127. doi: 10.3892/ijo.2020.5127 pmid: 33300049
[26]	Hu Q, Yu L, Chen R, et al. 5-aza-2′-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy[J]. Int J Gynecol Cancer, 2012, 22(6):951-959. doi: 10.1097/IGC.0b013e3182540160. doi: 10.1097/IGC.0b013e3182540160
[27]	Neal AS, Nunez M, Lai T, et al. Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia[J]. Reprod Sci, 2020, 27(9):1778-1790. doi: 10.1007/s43032-020-00175-w. doi: 10.1007/s43032-020-00175-w pmid: 32124398
[28]	Loukovaara M, Pasanen A, Bützow R. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer[J]. Cancer Med, 2021, 10(3):1034-1042. doi: 10.1002/cam4.3691. doi: 10.1002/cam4.3691
[29]	Huo X, Sun H, Cao D, et al. Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data[J]. Sci Rep, 2019, 9(1):9924. doi: 10.1038/s41598-019-46195-8. doi: 10.1038/s41598-019-46195-8 pmid: 31289358
[30]	Liu J, Ji C, Wang Y, et al. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer[J]. Cancer Cell Int, 2021, 21(1):365. doi: 10.1186/s12935-021-02038-z. doi: 10.1186/s12935-021-02038-z
[31]	Ying J, Xu T, Wang Q, et al. Exploration of DNA methylation markers for diagnosis and prognosis of patients with endometrial cancer[J]. Epigenetics, 2018, 13(5):490-504. doi: 10.1080/15592294.2018.1474071. doi: 10.1080/15592294.2018.1474071 pmid: 29912667
[32]	Zeng Z, Cheng J, Ye Q, et al. A 14-Methylation-Driven Differentially Expressed RNA as a Signature for Overall Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma[J]. DNA Cell Biol, 2020, 39(6):975-991. doi: 10.1089/dna.2019.5313. doi: 10.1089/dna.2019.5313 pmid: 32397815
[33]	Li X, Yin F, Fan Y, et al. Establishment and validation of a prognostic nomogram based on a novel five-DNA methylation signature for survival in endometrial cancer patients[J]. Cancer Med, 2021, 10(2):693-708. doi: 10.1002/cam4.3576. doi: 10.1002/cam4.3576
[34]	Ma J, Yang D, Ma XX. Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer[J]. Aging (Albany NY), 2021, 13(12):16287-16315. doi: 10.18632/aging.203157. doi: 10.18632/aging.203157
[35]	Zhai J, Li S, Li Y, et al. Data mining analysis of the prognostic impact of N(6)-methyladenosine regulators in patients with endometrial adenocarcinoma[J]. J Cancer, 2021, 12(15):4729-4738. doi: 10.7150/jca.50868. doi: 10.7150/jca.50868